Marinus Pharmaceuticals (NASDAQ:MRNS) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.06), MarketWatch Earnings reports.
Shares of NASDAQ:MRNS traded down $0.09 during trading on Tuesday, hitting $4.78. The company’s stock had a trading volume of 10,881 shares, compared to its average volume of 814,209. The company has a market cap of $203.84 million, a price-to-earnings ratio of -5.85 and a beta of 2.53. Marinus Pharmaceuticals has a fifty-two week low of $3.31 and a fifty-two week high of $10.54.
Several equities analysts have commented on the stock. ValuEngine downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. BidaskClub downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 15th. Zacks Investment Research upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. Mizuho restated a “buy” rating and issued a $13.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 25th. Finally, Cantor Fitzgerald set a $19.00 price target on shares of Marinus Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 25th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $19.67.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Further Reading: Why is the conference call important?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.